Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.

The oncologist - 1 Jun 2007

Rha Sun Young, Jeung Hei Cheul, Choi Yeon Ho, Yang Woo Ick, Yoo Jin Ho, Kim Byung Soo, Roh Jae Kyung, Chung Hyun Cheol

Abstract excerpt

PURPOSE: We examined the pattern of single-nucleotide polymorphisms (SNPs) of gemcitabine metabolism-related and target genes in breast cancer patients and evaluated their association with drug response or toxicity. PATIENTS AND METHODS: SNPs in deoxycytidine kinase (dCK), deoxycytidine monophosphate deaminase (DCTD), and ribonucleotide reductase M1 polypeptide (RRM1) were analyzed with genomic DNA of 10 breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Blotting, Western

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Gemcitabine

Share to Neutropenia

Share to Ribonucleoside Diphosphate Reductase

Share to Ribonucleotide Reductases

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 17602053
DOI: 10.1634/theoncologist.12-6-622

Genes

RRM1
DCTD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.PMID 17602053Read ↗

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.Semantic proximity Read ↗

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.Semantic proximity Read ↗

The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.Semantic proximity Read ↗

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.Semantic proximity Read ↗

RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.Semantic proximity Read ↗

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Semantic proximity Read ↗

Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy.Semantic proximity Read ↗

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.Semantic proximity Read ↗

Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial.Semantic proximity Read ↗

Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).Semantic proximity Read ↗

Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.Semantic proximity Read ↗

Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.